Back to discover

Protein / target

Angiotensin-converting enzyme

Encoded byACEP12821Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
22
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Mitogen-activated protein kinase kinase binding

Strongest disease association

Renal tubular dysgenesis

Via encoding gene ACE · Genetic evidence · score 0.89

Therapeutic position

Established drug target

Small molecules

Research activity

Emerging research

23 papers · latest 2020

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Dipeptidyl carboxypeptidase that removes dipeptides from the C-terminus of a variety of circulating hormones, such as angiotensin I, bradykinin or enkephalins, thereby playing a key role in the regulation of blood pressure, electrolyte homeostasis or synaptic plasticity.

View complete UniProt function annotation

Dipeptidyl carboxypeptidase that removes dipeptides from the C-terminus of a variety of circulating hormones, such as angiotensin I, bradykinin or enkephalins, thereby playing a key role in the regulation of blood pressure, electrolyte homeostasis or synaptic plasticity (PubMed:15615692, PubMed:20826823, PubMed:2558109, PubMed:4322742, PubMed:7523412, PubMed:7683654). Composed of two similar catalytic domains, each possessing a functional active site, with different selectivity for substrates (PubMed:10913258, PubMed:1320019, PubMed:1851160, PubMed:19773553, PubMed:7683654, PubMed:7876104). Plays a major role in the angiotensin-renin system that regulates blood pressure and sodium retention by the kidney by converting angiotensin I to angiotensin II, resulting in an increase of the vasoconstrictor activity of angiotensin (PubMed:11432860, PubMed:1851160, PubMed:19773553, PubMed:23056909, PubMed:4322742). Also able to inactivate bradykinin, a potent vasodilator, and therefore enhance the blood pressure response (PubMed:15615692, PubMed:2558109, PubMed:4322742, PubMed:6055465, PubMed:6270633, PubMed:7683654). Acts as a regulator of synaptic transmission by mediating cleavage of neuropeptide hormones, such as substance P, neurotensin or enkephalins (PubMed:15615692, PubMed:6208535, PubMed:6270633, PubMed:656131). Catalyzes degradation of different enkephalin neuropeptides (Met-enkephalin, Leu-enkephalin, Met-enkephalin-Arg-Phe and possibly Met-enkephalin-Arg-Gly-Leu) (PubMed:2982830, PubMed:6270633, PubMed:656131). Acts as a regulator of synaptic plasticity in the nucleus accumbens of the brain by mediating cleavage of Met-enkephalin-Arg-Phe, a strong ligand of Mu-type opioid receptor OPRM1, into Met-enkephalin (By similarity). Met-enkephalin-Arg-Phe cleavage by ACE decreases activation of OPRM1, leading to long-term synaptic potentiation of glutamate release (By similarity). Also acts as a regulator of hematopoietic stem cell differentiation by mediating degradation of hemoregulatory peptide N-acetyl-SDKP (AcSDKP) (PubMed:26403559, PubMed:7876104, PubMed:8257427, PubMed:8609242). Acts as a regulator of cannabinoid signaling pathway by mediating degradation of hemopressin, an antagonist peptide of the cannabinoid receptor CNR1 (PubMed:18077343). Involved in amyloid-beta metabolism by catalyzing degradation of Amyloid-beta protein 40 and Amyloid-beta protein 42 peptides, thereby preventing plaque formation (PubMed:11604391, PubMed:16154999, PubMed:19773553). Catalyzes cleavage of cholecystokinin (maturation of Cholecystokinin-8 and Cholecystokinin-5) and Gonadoliberin-1 (both maturation and degradation) hormones (PubMed:10336644, PubMed:2983326, PubMed:7683654, PubMed:9371719). Degradation of hemoregulatory peptide N-acetyl-SDKP (AcSDKP) and amyloid-beta proteins is mediated by the N-terminal catalytic domain, while angiotensin I and cholecystokinin cleavage is mediated by the C-terminal catalytic region (PubMed:10336644, PubMed:19773553, PubMed:7876104)

Subcellular location

Cell membraneCytoplasmSecreted
Domains and Gene Ontology detail (59)

Domains & features

Peptidase M2 1Peptidase M2 2

Gene Ontology

  • Cendosome
  • Cexternal side of plasma membrane
  • Cextracellular exosome
  • Cextracellular region
  • Cextracellular space
  • Clysosome
  • Cplasma membrane
  • Factin binding
  • Fbradykinin receptor binding
  • Fcalmodulin binding
  • Fchloride ion binding
  • Fendopeptidase activity

1306 aa · 150 kDa · 4 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Synaptic signallingUniProtCell migrationGOProteolysisGOMetabolic enzyme activityGOTranscriptional regulationGO
View supporting evidence

Synaptic signalling

  • ·Dipeptidyl carboxypeptidase that removes dipeptides from the C-terminus of a variety of…

Cell migration

  • ·regulation of smooth muscle cell migration

Proteolysis

  • ·endopeptidase activity
  • ·exopeptidase activity
  • ·metallocarboxypeptidase activity
  • ·metallodipeptidase activity

Metabolic enzyme activity

  • ·amyloid-beta metabolic process
  • ·hormone metabolic process
  • ·regulation of angiotensin metabolic process

Transcriptional regulation

  • ·negative regulation of gene expression
  • ·post-transcriptional regulation of gene expression
View underlying pathways (1)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

AGTKNG1RENAGTR1ACE2AGTR2BDKRB2ALBNR3C2MMEL1ACE

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

3 medicines · 11 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Heart Failure3 medicines
Hypertension3 medicines
Myocardial Infarction3 medicines
Diabetes Mellitus2 medicines
Stroke2 medicines
Coronary Artery Disease1 medicine
Diabetic Nephropathies1 medicine
Diabetic Retinopathy1 medicine
Renal Insufficiency1 medicine
Ventricular Dysfunction, Left1 medicine
Broader indication categories (1)
Cardiovascular Diseases3 medicines

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

22 medicines meet Open Targets' target-level approved-medicine definition; the 3 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

3

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

Captopril
Narrow target profileApprovedInhibitor

Angiotensin-converting enzyme inhibitor

Indicated for Diabetic Nephropathies, Diabetic Retinopathy, Heart Failure, Hypertension

Direct interaction with this protein · Only this protein recorded as a target

Lisinopril
Narrow target profileApprovedInhibitor

Angiotensin-converting enzyme inhibitor

Indicated for Diabetes Mellitus, Heart Failure, Hypertension, Myocardial Infarction

Direct interaction with this protein · Only this protein recorded as a target

ramipril
Narrow target profileApprovedInhibitor

Angiotensin-converting enzyme inhibitor

Indicated for Coronary Artery Disease, Diabetes Mellitus, Heart Failure, Hypertension

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene ACE

Gene-level evidence surfaced through the gene ACE that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Hypertension
0.96Well supported

Genetic evidence dominant · Open Targets 0.74

Renal tubular dysgenesis
0.91Well supported

Genetic evidence dominant · Open Targets 0.72

Cardiovascular Diseases
0.91Well supported

Clinical evidence dominant · Open Targets 0.69

Diabetes Mellitus
0.90Well supported

Clinical evidence dominant · Open Targets 0.66

Diabetic Nephropathies
0.88Well supported

Clinical evidence dominant · Open Targets 0.69

View evidence synthesis (5)
HypertensionWell supported
0.96
agreement 0.851.00
Genetic48%Clinical44%Literature8%

Open Targets aggregate 0.74 · 3 independent evidence families

Renal tubular dysgenesisWell supported
0.91
agreement 0.791.00
Genetic84%Animal model15%Literature1%Genetic literaturedup

Open Targets aggregate 0.72 · 3 independent evidence families · 1 not counted as duplicate

Cardiovascular DiseasesWell supported
0.91
agreement 0.801.00
Clinical51%Genetic45%Literature4%

Open Targets aggregate 0.69 · 3 independent evidence families

Diabetes MellitusWell supported
0.90
agreement 0.800.99
Clinical46%Genetic37%Animal model10%Literature8%

Open Targets aggregate 0.66 · 4 independent evidence families

Diabetic NephropathiesWell supported
0.88
agreement 0.760.99
Clinical54%Genetic literature36%Literature10%

Open Targets aggregate 0.69 · 3 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Hypertension0.74
Renal tubular dysgenesis0.72
Renal tubular dysgenesis of genetic origin0.72
Cardiovascular Diseases0.69
Diabetic Nephropathies0.69
Diabetes Mellitus0.66
Heart Failure0.62
Myocardial Infarction0.61

Drug development

24 compounds recorded · 22 approved · 2 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 3 drugs that target this protein in Forefront's canonical graph (3 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)
CILAZAPRILApproval
ENALAPRIL MALEATEApproval
PERINDOPRIL ARGININEApproval
ENALAPRILATApproval
CAPTOPRILApproval
DELAPRILApproval
BENAZEPRIL HYDROCHLORIDEApproval
MOEXIPRIL HYDROCHLORIDEApproval
LISINOPRIL ANHYDROUSPhase 3
IMIDAPRILApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (11)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

proximal tubular degenerationLynch et al. (2017)increased urine excretionLynch et al. (2017)gastrointestinal hemorrhagic erosion/ulcerLynch et al. (2017)diabetes mellitusClinPGxinterstitial cell infiltrationLynch et al. (2017)increased risk spontaneous abortionLynch et al. (2017)decreased blood pressureLynch et al. (2017)increased urinary sodium excretionLynch et al. (2017)aspirin intoleranceClinPGxjuxtaglomerular cell hyperplasiaLynch et al. (2017)hepatocytic vacuolar degenerationLynch et al. (2017)decreased bone marrow erythropoiesisLynch et al. (2017)

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ACTIVE_NOT_RECRUITING · via ramipril · NCT04173949

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 3 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Product recall2026-08-24

    Recall (Class II): RAMIPRIL

    fda · safety · fda · via ramipril

  2. Regulatory approval2026-08-20

    Approval: LISINOPRIL (ANDA218419)

    fda · regulatory · fda · via Lisinopril

  3. Label change2026-08-19

    Label change: RAMIPRIL (ANDA091604)

    fda · regulatory · fda · via ramipril

  4. Label change2026-08-07

    Label change: RAMIPRIL (ANDA077004)

    fda · regulatory · fda · via ramipril

  5. Label change2026-08-07

    Label change: RAMIPRIL (ANDA077626)

    fda · regulatory · fda · via ramipril

  6. Label change2026-08-07

    Label change: RAMIPRIL (ANDA077900)

    fda · regulatory · fda · via ramipril

  7. Label change2026-08-07

    Label change: RAMIPRIL (ANDA077900)

    fda · regulatory · fda · via ramipril

  8. Product recall2024-10-23

    Recall (Class II): RAMIPRIL

    fda · safety · fda · via ramipril

  9. New publication2013-08-01
    Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication.

    The British journal of surgery · 2013 · 15 citations · Europe PMC · via ramipril

  10. New publication2004-09-01
    Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.

    The New England journal of medicine · 2004 · 1,345 citations · Europe PMC · via Captopril

  11. New publication2003-11-10
    Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

    The New England journal of medicine · 2003 · 1,589 citations · Europe PMC · via Captopril

  12. New publication2000-09-01
    A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.

    Circulation research · 2000 · 2,163 citations · Europe PMC · via Lisinopril

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.

Research activity

23 papers · to 2020

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.

Gurwitz D · Drug development research · 2020

Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2.

Jackson DJ · The Journal of allergy and clinical immunology · 2020

Immunogenicity of a DNA vaccine candidate for COVID-19.

Smith TRF · Nature communications · 2020

ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome.

Devaux CA · Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2020

Europe PMC papers linked directly to this protein.